News
STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
As new cancer drugs arrive, regulators and doctors still struggle with when to use drugs based on earlier data and when to wait for survival data. #ASCO23 […]
Biotechnology
News
STAT+: Gilead’s CAR-T therapy prolongs survival in key blood cancer trial
Proving a meaningful survival benefit for patients with a type of blood cancer represents another milestone for CAR-T therapy. #ASCO23 […]
News
‘Robbing Peter to pay Paul’: Obesity experts debate risks of new weight loss drugs
Amid rising demand for drugs like Wegovy and Ozempic that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances… […]
News
STAT+: Doudna talks cost, access issues looming over first CRISPR therapy
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going… […]
News
STAT+: Gilead foresees more growth in its HIV drugs
Gilead’s CEO believes the foundation of the company will continue to be its HIV franchise, particularly PrEP. #STATBreakthrough […]
News
Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business
What’s the future of Alzheimer’s disease treatment? How do you pivot from a pandemic? And how successful can Wegovy get? Find out on the new episode of “The Readout LOUD.” […]
News
STAT+: CAR-T research is flourishing but is hampered by outdated precautions, experts say
A gathering of experts in CAR-T cancer therapy at #STAT breakthrough express optimism about making therapy faster and more accessible, while also raising concerns about falling behind China. […]
News
For Eli Lilly’s head scientist, Alzheimer’s results cap a 25-year scientific quest
“Probably any words I use to describe my emotions at seeing this data will understate it,” said Daniel Skovronsky, Eli Lilly’s head scientist. […]
News
STAT+: A biotech upstart takes on cancer by crowdsourcing the immune system’s natural killers
ImmuneBridge, a San Francisco-based startup, is developing cancer immunotherapies based on so-called natural killer cells. […]
News
STAT+: ‘It was my call’: Stanford president defends decision not to correct key paper in misconduct investigation
Stanford president Marc Tessier-Lavigne took responsibility for the decision not to correct or retract a paper at the heart of scientific-misconduct allegations. […]
